PharmaBlock Sciences (Nanjing), Inc. Class A

PharmaBlock Sciences (Nanjing), Inc. Class A

SSZSE:300725
42.43
CNY
-0.52
(-1.21%)
0.96EPS
57.52P/E
12.94BMarket Cap
Apr 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.46
0.71
1.24
1.42
1.9
2.57
3.55
5.49
6.08
8.02
8.65
8.46
9.46
9.51
Basic EPS, GAAP
0.14
0.21
0.18
0.27
0.47
0.72
0.82
0.99
2.46
1.58
0.99
1.1
0.88
0.96
Free Cash Flow per Basic Share
0.1
-0.09
0.16
-0.12
0.04
0.6
-0.25
1.06
-1.35
-1.57
-0.35
0.93
2.53
- -
Dividend per Share
- -
0.06
0.09
- -
- -
0.08
0.14
0.12
0.11
0.17
0.21
0.39
0.31
0.38
Book Value per Share
0.55
0.69
1.15
1.76
2.66
3.23
3.94
10.04
12.16
13.31
14.19
14.96
26.95
19.62
Tangible Book Value per Share
0.54
0.67
1.13
1.64
2.52
3.06
3.64
9.69
9.81
10.97
11.85
12.64
24.98
17.61
Basic Weighted Avg Shares
127
107
110
133
144
186
186
186
198
199
199
200
209
230
Sales/Revenue/Turnover
59
77
136
188
273
478
662
1,022
1,202
1,595
1,725
1,689
1,974
2,190
Operating Margin (%)
35.76
33.07
16.53
21.76
29.58
30.15
25.2
21.42
23.41
18.59
17.16
17.8
12.9
13.29
Depreciation Expense
3
3
4
9
12
17
21
24
55
88
116
133
140
- -
Net Income, GAAP
18
22
20
36
67
133
152
184
487
314
197
220
184
222
Effective Tax Rate (%)
15.45
14.78
26.17
21.52
12.03
12.89
11.77
9.93
0.79
- -
10.85
11.79
11.5
11.55
Profit Margin (%)
31.17
29.32
14.64
19.17
24.59
27.89
22.96
18.02
40.49
19.7
11.44
13
9.31
10.12
Working Capital
41
54
107
151
376
356
258
1,396
1,015
1,921
1,762
1,968
2,054
2,030
LT Debt
- -
- -
- -
- -
- -
- -
- -
2
24
1,392
1,139
1,130
8
17
Total Equity
70
87
147
254
504
600
741
1,895
2,628
2,658
2,832
2,988
6,300
4,586
Return on Invested Capital (%)
- -
25.58
14.8
15.5
16.99
21.87
20.05
12.37
19.46
- -
3.73
4.93
3.45
4.64
Return on Capital (%)
- -
28.96
17.13
18.47
17.49
23.58
21.73
13.11
19.03
- -
5.82
6.08
3.96
4.6
Return on Common Equity (%)
- -
28.62
17.13
18.47
18.14
24.36
22.69
13.98
22.51
12.36
7.19
7.54
3.96
5.4

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
105
107
9
LT Borrowings
- -
- -
- -
LT Finance Leases
8
15
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
234
234
234
Market Capitalization
8,476
8,557
12,941

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,646
2,846
2,782
Cash, Cash Equivalents & STI
1,063
1,241
1,393
Accounts Receivable, Net
431
379
467
Inventories
655
714
748
Total Current Liabilities
625
722
752
Payables & Accruals
- -
- -
- -
ST Debt
105
107
9
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
53.27%
32.55%
110.88%
Free Cash Flow
43.62%
-96.09%
185.45%
Net Income, GAAP
38.73%
17.29%
-16.31%
Sales/Revenue/Turnover
32.45%
14.65%
16.93%
Total Cash Common Dividend
2,560.16%
29.2%
-15.68%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
377
367
383
561
1,689
2025
455
465
- -
555
1,974
2026
508
551
575
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.25
0.25
0.17
0.44
1.1
2025
0.18
0.18
- -
0.32
0.88
2026
0.21
0.22
0.22
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.35
0.02
0.01
0.39
2025
- -
0.34
- -
-0.02
0.31
2026
- -
0.28
0.1
- -
- -

Company Description

CEO
Min Min Yang
Full Time Employees
2,593
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
No. 81, Huasheng Road Nanjing JS China 210032
IPO Date
Nov 10, 2017
Business
PharmaBlock Sciences (Nanjing), Inc. (300725.SZ) engages primarily in the research, development, production and sales of pharmaceutical molecular building blocks and related chemistry services; it offers a rationally designed collection of novel building blocks for drug discovery and development supplied from lab-scale to commercial volumes, building blocks-driven compound libraries, custom chemistry research services, contract development and manufacturing organization (CDMO) services for raw starting materials (RSMs), key intermediates, active pharmaceutical ingredients (APIs), drug substances and drug products including solid dosage forms and packaging, as well as low-carbon manufacturing technologies and regulatory support. Founded in 2008 and headquartered in Nanjing, Jiangsu Province, China, the company operates seven sites across China, the United States and Switzerland, including a major facility in the Greater Philadelphia area and a recently expanded R&D center in West Chester, Pennsylvania; it serves top global pharmaceutical companies, biotech firms and partners in the pharmaceutical R&D and commercial manufacturing sectors worldwide. Recent developments include the approval of a final cash dividend for A shares related to fiscal year 2024 payable in May 2025, ongoing expansion of GMP capabilities through its new U.S. R&D facility opened in 2023 to support increased project delivery, and recognition with the 2023 CMO Excellence in Green Chemistry Award alongside major peers, underscoring its strategic focus on sustainable, innovative chemistry processes.